Platinum-based doublet chemotherapy is the standard first-line treatment for advanced NSCLC when genomic testing reveals no activating epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 rearrangement [5], with objective response rates between 15~ 30% [6, 7]. This evidence concerns the gene ALK and non-small cell lung carcinoma.